In recent years new diagnostic methods have been developed, based on the detection and quantification of the PCA3 gene. PCA3 is a prostate cancer-specific gene as it is only produced by cells that have undergone transformation to prostate cancer.
The main advantage of measuring this molecular marker is that the result of this analysis is not affected by non-cancerous prostate diseases such as Benign Prostatic Hyperplasia (BPH) or Prostatitis.
With a simple urine sample prostate cancer can be identified at an early stage
Prostate cancer screening with PSA blood test and digital rectal examination (DRE) is 24-37% (1).
This is because PSA is a protein normally produced by prostate cells that when its value is increased in blood serum it is only an indicator of inflammation of the prostatic tissue, which does not mean cancer.
ProstaGEN
- Digital and in-app reporting
- Appointment with an interpreter